Synthetic peptides corresponding to six predicted immunogenic sites on human rhinovirus type 2 (HRV2) have been tested for their reactivity with an anti-virion antibody and for their ability to elicit neutralizing antibody. Four of the peptides reacted with HRV2 antiserum in an indirect ELISA. Rabbit antisera produced to three of these four peptides, one each from VP1, VP2 and VP3, reacted with the virus in an indirect ELISA and with the corresponding proteins by Western blotting. Furthermore, antiserum to one of the peptides, designed to cover the neutralization epitope NIm-II on VP2, not only reacted well in a sandwich ELISA and in an immunoprecipitation test but also neutralized virus infectivity.
The human rhinovirus (HRV) particle is composed of one molecule of single-stranded RNA plus 60 copies of the structural proteins VP 1 and VP3, 58 copies of VP2 and VP4 and two copies of their precursor VP0 (Medappa et al., 1971 ; Rueckert, 1976) . The recent publication of the atomic structure of HRV type 14 (Rossmann et al., 1985) has provided detailed information on the location and structure of VP1, VP2 and VP3 as they appear on the surface of the intact virion. Furthermore, the positions of amino acid substitutions found in neutralization-resistant mutants selected by a number of monoclonal antibodies have been used to identify four antigenic sites on the virus particle Sherry et al., 1986) . These sites have been referred to as NIm-IA, NIm-IB, NIm-II and NIm-III according to the viral protein on which they are chiefly located.
By reference to a computer graphic model of H RV 14 (generated by Dr D. Stuart, Department of Molecular Biophysics, Oxford University, U.K. using coordinates provided by Dr M. G. Rossmann) and by sequence alignment of HRV14 with HRV2, another serotype of the virus (Stanway et al., 1984; Skern et al., 1985; Callahan et al., 1985) , we have selected a number of potentially important immunogenic sites on HRV2 (three from VP1, one from VP2 and two from VP3) for assessment using synthetic peptides. The sequences and locations of the HRV2 peptides produced are given in Table 1 . Synthesis was carried out using an adaptation of the Merrifield (1963) technique described by Houghten (1985) . Each peptide had an additional nonnatural cysteine residue at its C-terminus to facilitate coupling to keyhole limpet haemocyanin (KLH) .
The peptides were initially tested in vitro for their reactivity with rabbit anti-HRV2 serum using an indirect ELISA, in which a range of concentrations of peptides bound to the solid phase was screened with an excess of antiserum. Although this technique was used as a screen for immunoreactive peptides it should be noted that some important conformation-dependent antibodies may not have been detected due to the poor recognition of a linear peptide bound to a solid phase. Nevertheless, the assay identified four reactive peptides, two from VP1, one from VP2 and one from VP3 (Table 1) . These four peptides were therefore selected for immunization after coupling to KLH with N-maleimidobenzoyl-N-hydroxysuccinimide through the cysteine (Liu et al., 1979) . Pairs of rabbits were inoculated intramuscularly with 500 gg of each peptide emulsified with complete Freund's adjuvant and reinoculated subcutaneously 42 days later, with 0000-7810 Short communication 1 This sequence is not contiguous on the VP1 primary structure. Rossmann et al. (1985) . the same dose emulsified with incomplete Freund's adjuvant. Serum samples were monitored at 14 day intervals for anti-peptide activity. All the rabbits produced anti-peptide antibodies that were detectable within 14 days of the first inoculation, and in the final bleeds collected 28 days after revaccination the anti-peptide activity as measured by indirect ELISA ranged from 103.7 to 104.7 (Table 2) . Prebleed sera from all eight rabbits were negative in all assays. The anti-peptide sera were subsequently examined for anti-HRV2 activity using several different assay systems, namely indirect ELISA, sandwich ELISA, immunoprecipitation and neutralization ( Table 2 ). All the antisera reacted with HRV2 in an indirect ELISA, with antisera to peptides 3, 4 and 6 giving significantly higher titres (103 1 to 1052) than antisera to peptide 2 (101 .s to 10 ~ .8). However, only the antiserum from rabbit number 5 inoculated with peptide 4 from VP2 reacted well in a sandwich ELISA. The difference in results with the two assays is probably related to the degree of distortion of the virus particles induced by the method of binding to the solid phase (McCullough et al., 1985) . It is known that direct binding to a plastic surface, as in the indirect ELISA, causes a distortion of another picornavirus, foot-and-mouth On: Fri, 21 Dec 2018 23:58:41 disease virus, exposing antigenic sites not normally accessible to peptide antibodies (Francis et al., 1987) . The sandwich ELISA imposes less physical alteration of virus particles since they are trapped by immobilized antibody. Since both ELISA techniques may distort the virus, to a greater or lesser extent, sera were also allowed to react in solution with purified [3SS]methionine-labelled HRV2 particles and precipitated using staphylococcus A ghosts. Only the sera to peptide 4 showed any significant precipitation of the virus (Table 2) . However, the extent of precipitation observed was significantly different between the two rabbit sera tested (Fig. 1) . The antiserum from rabbit number 5 precipitated > 9 0~ of the labelled virus while that from rabbit number 6 precipitated only 58~o, in the same assay. This result was probably due to a difference in the overall functional affinities of the two antisera for native rhinovirus particles. It is interesting to note that the antiserum that was more active in precipitating the virus was also the one that reacted in the sandwich ELISA.
All the peptide antisera were also tested for their ability to neutralize the virus. Undiluted antiserum and a 1:4 dilution of each antiserum were incubated with a range of virus dilutions and the difference in titre (loglo) obtained with virus plus normal rabbit serum and virus plus anti-peptide serum was taken as the neutralization index. Using this technique only the antiserum to peptide 4 possessed any neutralizing activity, with rabbit number 5 antiserum having significantly greater activity than that from rabbit number 6 ( Table 2) . It was this antiserum that reacted best in the sandwich ELISA and immunoprecipitation tests. Since both sera had similar levels of anti-peptide activity, the differences observed in the neutralizing antibody assay must be due to qualitative differences in the antibody populations with respect to the conformation of the epitope they recognize. The ability of peptide 4, which was designed to cover NIm-II on the virus, to elicit neutralizing antibodies was in accord with recently published work by Skern et al. (1987) which identified the same site using a neutralizing monoclonal antibody. Indeed our peptide sequence only differed from their site by three amino acids at the N-terminus. Therefore, two totally independent lines of investigation have identified the same neutralization site on VP2 of HRV2.
Finally, Western blotting was performed to determine whether the peptide antisera recognized isolated viral proteins in a specific manner. In contrast to the polyclonal anti-HRV2 serum, which failed to react, each of the anti-peptide sera reacted with the corresponding virus protein, with antisera to peptides 3, 4 and 6 having the highest reactivity (Fig. 2) . These observations support the indirect ELISA results. Furthermore, the monoclonal antibody described by Skern et al. (1987) covering our peptide 4 site also reacted in Western blots. In general the reactions were protein-specific although peptide 3 antiserum cross-reacted with VP2 and VP3, and peptide 4 antiserum cross-reacted with VP 1 to a limited extent. However, the level of cross-reactivity was so low (< 5 ~) that the antisera would provide useful marker reagents for the virus proteins. The reason for this low level of cross-reactivity has not been investigated.
In conclusion we have produced synthetic peptides to six predicted immunogenic determinants on HRV2, four of which react with rabbit anti-HRV2 serum. Of these four peptides, three produced antisera which reacted well with virus particles in an indirect ELISA and by Western blotting. Moreover, antiserum to peptide 4, covering NIm-II, reacts with virus in a sandwich ELISA and an immunoprecipitation test, and neutralizes its infectivity in vitro. We believe that this is the first report of neutralizing activity induced by rhinovirus synthetic peptides.
